Uncategorized
Mirum, Incyte bolster case for approval in rare bone disease despite mid-stage miss
While falling short of statistical significance, Incyte and Mirum Pharmaceuticals’ ALK2 inhibitor showed a “clear benefit” in reducing abnormal bone formation in a Phase 2 study of fibrodysplasia ossificans progressiva.